Abstract
Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086.
Methods: This was a randomised, placebo-controlled, parallel group study in subjects with persistent asthma (n=135) who received GW870086 (2, 3, or 4 mg, once-daily) or placebo.
Results: Improvements in forced expiratory volume in one second (FEV1) were seen following all three doses of GW870086 relative to placebo. Mean improvements (95% confidence interval) of: 0.172 L (0.015, 0.329), 0.105 L (-0.053, 0.263) and 0.159 L (0.001, 0.316) were observed for 2 mg, 3 mg and 4 mg, respectively, at Day 28. Peak expiratory flow rate results were consistent with FEV1 and rescue medication was administered more frequently in the placebo group than all three GW870086 treatment arms.
Conclusion: This study provided a positive outcome with all doses of GW870086 demonstrating improvements in lung function compared with placebo.
Keywords: Diskhaler, glucocorticoid, inhaled corticosteroid, repeat dose.
Current Drug Therapy
Title:Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial
Volume: 8 Issue: 2
Author(s): Philippe Bareille, Kelly Hardes, Jonathan Robertson, Angela Davis and Ann Allen
Affiliation:
Keywords: Diskhaler, glucocorticoid, inhaled corticosteroid, repeat dose.
Abstract: Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086.
Methods: This was a randomised, placebo-controlled, parallel group study in subjects with persistent asthma (n=135) who received GW870086 (2, 3, or 4 mg, once-daily) or placebo.
Results: Improvements in forced expiratory volume in one second (FEV1) were seen following all three doses of GW870086 relative to placebo. Mean improvements (95% confidence interval) of: 0.172 L (0.015, 0.329), 0.105 L (-0.053, 0.263) and 0.159 L (0.001, 0.316) were observed for 2 mg, 3 mg and 4 mg, respectively, at Day 28. Peak expiratory flow rate results were consistent with FEV1 and rescue medication was administered more frequently in the placebo group than all three GW870086 treatment arms.
Conclusion: This study provided a positive outcome with all doses of GW870086 demonstrating improvements in lung function compared with placebo.
Export Options
About this article
Cite this article as:
Bareille Philippe, Hardes Kelly, Robertson Jonathan, Davis Angela and Allen Ann, Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial, Current Drug Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/1574885511308020001
DOI https://dx.doi.org/10.2174/1574885511308020001 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acne in the Adult
Mini-Reviews in Medicinal Chemistry Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design The Colostrum Proteome, Ruminant Nutrition and Immunity: A Review
Current Protein & Peptide Science Targeting Lentiviral Vectors for Cancer Immunotherapy
Current Cancer Therapy Reviews Colon as Target for Drug Delivery
Current Drug Therapy Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease
Current Neuropharmacology Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Immunomodulatory Role of Vitamin D in Respiratory Diseases
Current Respiratory Medicine Reviews Bronchiolitis, Bronchitis, Asthma Exacerbation, Bronchopneumonia, Pneumonia: A Didactic Stepwise Approach
Current Respiratory Medicine Reviews Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research